Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2003-03-14
• Target enrollment: 0
• Participant gender: All

Summary

This trial is conducted in Europe. The aim of this trial investigate the the long-term safety of biphasic insulin aspart 30 in subjects with type 2 diabetes.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Signed informed consent obtained before any trial-related activities

• Completed the trial BIAsp-1236

Exclusion Criteria:

• Planned changes in use of any prescription medication that may interfere with glucose regulation

• Known or suspected allergy to trial products or related products

• Women who are having the intention of becoming pregnant, or are judged not to be using adequate contraceptive measures

• Any other significant condition or concomitant disease or any condition that would interfere with participation as judged by the Investigator